EA201491655A1 - Новый слитый fgfr3 - Google Patents
Новый слитый fgfr3Info
- Publication number
- EA201491655A1 EA201491655A1 EA201491655A EA201491655A EA201491655A1 EA 201491655 A1 EA201491655 A1 EA 201491655A1 EA 201491655 A EA201491655 A EA 201491655A EA 201491655 A EA201491655 A EA 201491655A EA 201491655 A1 EA201491655 A1 EA 201491655A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gene
- probes
- polynucleotide
- primer
- fgfr3
- Prior art date
Links
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 239000000523 sample Substances 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000001514 detection method Methods 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Настоящее изобретение имеет целью выявить полинуклеотид в качестве нового гена, ответственного за рак, и, соответственно, предоставить способ детектирования полинуклеотида и полипептида, кодируемого полинуклеотидом, и набор для детектирования, набор зондов и набор праймеров для детектирования. Целью настоящего изобретения также является предоставление фармацевтической композиции для лечения рака. Способ детектирует слитый ген, составленный из части гена FGFR3 и части гена ТАСС3, или слитый белок, кодируемый слитым геном. Набор праймеров, набор зондов или набор для детектирования содержит смысловой праймер и набор зондов, спроектированных по части, кодирующей FGFR3, и антисмысловой праймер и набор зондов, спроектированных по части, кодирующей ТАСС3. Поскольку ингибитор полипептида демонстрирует противоопухолевый эффект, предоставляется фармацевтическая композиция для лечения рака, который является положительным либо по слитому гену, либо по полипептиду.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012052147 | 2012-03-08 | ||
JP2012195451 | 2012-09-05 | ||
JP2012280325 | 2012-12-21 | ||
PCT/JP2013/056225 WO2013133351A1 (ja) | 2012-03-08 | 2013-03-07 | 新規fgfr3融合体 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491655A1 true EA201491655A1 (ru) | 2015-01-30 |
EA029140B1 EA029140B1 (ru) | 2018-02-28 |
Family
ID=49116820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491655A EA029140B1 (ru) | 2012-03-08 | 2013-03-07 | Новый слитый fgfr3 |
Country Status (17)
Country | Link |
---|---|
US (2) | US9481911B2 (ru) |
EP (1) | EP2824181B1 (ru) |
JP (1) | JP6107812B2 (ru) |
KR (4) | KR102106962B1 (ru) |
CN (1) | CN104379740B (ru) |
AU (1) | AU2013228389A1 (ru) |
BR (1) | BR112014021897B1 (ru) |
CA (1) | CA2865388C (ru) |
EA (1) | EA029140B1 (ru) |
ES (1) | ES2702305T3 (ru) |
HK (1) | HK1205528A1 (ru) |
MX (1) | MX365214B (ru) |
PH (1) | PH12014501918A1 (ru) |
PL (1) | PL2824181T3 (ru) |
PT (1) | PT2824181T (ru) |
WO (1) | WO2013133351A1 (ru) |
ZA (1) | ZA201406570B (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
WO2014018673A2 (en) | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
EA031631B1 (ru) | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
AU2013337264B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
WO2014139145A1 (en) | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
WO2014165710A2 (en) * | 2013-04-05 | 2014-10-09 | Life Technologies Corporation | Gene fusions |
AR097455A1 (es) * | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
WO2015093557A1 (ja) * | 2013-12-19 | 2015-06-25 | 独立行政法人国立がん研究センター | 胃がんの責任因子としての新規融合遺伝子 |
EP3098312B1 (en) * | 2014-01-24 | 2023-07-19 | Japanese Foundation For Cancer Research | Novel fusant and method for detecting same |
WO2015120094A2 (en) * | 2014-02-04 | 2015-08-13 | Mayo Foundation For Medical Education And Research | Method of identifying tyrosine kinase receptor rearrangements in patients |
LT3122359T (lt) | 2014-03-26 | 2021-03-25 | Astex Therapeutics Ltd. | Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai |
SI3122358T1 (sl) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
JP6524833B2 (ja) * | 2015-07-17 | 2019-06-05 | コニカミノルタ株式会社 | 蛍光体集積ナノ粒子を用いたfishまたは免疫染色スライドの封入方法 |
EP3353177B1 (en) | 2015-09-23 | 2020-06-03 | Janssen Pharmaceutica NV | Tricyclic heterocycles for the treatment of cancer |
RU2747644C2 (ru) | 2015-09-23 | 2021-05-11 | Янссен Фармацевтика Нв | Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака |
CN111424081B (zh) * | 2020-04-13 | 2023-04-25 | 广东省妇幼保健院 | 基于多重荧光定量pcr技术检测软骨发育不全fgfr3基因突变的引物、探针和试剂盒 |
US11505611B2 (en) | 2020-08-21 | 2022-11-22 | Genzyme Corporation | FGFR3 antibodies and methods of use |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1692085A4 (en) | 2003-11-07 | 2010-10-13 | Novartis Vaccines & Diagnostic | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA |
CN1976706B (zh) * | 2003-11-07 | 2012-01-18 | 诺华疫苗和诊断公司 | 抑制fgfr3及治疗多发性骨髓瘤 |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
AR078411A1 (es) | 2009-05-07 | 2011-11-09 | Lilly Co Eli | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
EP2761300A4 (en) | 2011-09-27 | 2015-12-02 | Univ Michigan | FUSIONS OF RECURRENT GENES IN BREAST CANCER |
KR102032007B1 (ko) * | 2012-02-28 | 2019-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 질소 함유 방향족 헤테로환 화합물 |
WO2014018673A2 (en) * | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
EA031631B1 (ru) | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
AU2013337264B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
-
2013
- 2013-03-07 WO PCT/JP2013/056225 patent/WO2013133351A1/ja active Application Filing
- 2013-03-07 KR KR1020147028041A patent/KR102106962B1/ko active IP Right Grant
- 2013-03-07 MX MX2014010823A patent/MX365214B/es active IP Right Grant
- 2013-03-07 US US14/383,199 patent/US9481911B2/en active Active
- 2013-03-07 PT PT13757006T patent/PT2824181T/pt unknown
- 2013-03-07 KR KR1020227002486A patent/KR20220017512A/ko active Application Filing
- 2013-03-07 CA CA2865388A patent/CA2865388C/en active Active
- 2013-03-07 BR BR112014021897-8A patent/BR112014021897B1/pt active IP Right Grant
- 2013-03-07 PL PL13757006T patent/PL2824181T3/pl unknown
- 2013-03-07 AU AU2013228389A patent/AU2013228389A1/en not_active Abandoned
- 2013-03-07 JP JP2014503528A patent/JP6107812B2/ja active Active
- 2013-03-07 EP EP13757006.5A patent/EP2824181B1/en not_active Revoked
- 2013-03-07 ES ES13757006T patent/ES2702305T3/es active Active
- 2013-03-07 KR KR1020237024475A patent/KR20230111270A/ko not_active Application Discontinuation
- 2013-03-07 KR KR1020207012045A patent/KR20200046135A/ko active Application Filing
- 2013-03-07 EA EA201491655A patent/EA029140B1/ru not_active IP Right Cessation
- 2013-03-07 CN CN201380012774.XA patent/CN104379740B/zh active Active
-
2014
- 2014-08-26 PH PH12014501918A patent/PH12014501918A1/en unknown
- 2014-09-08 ZA ZA2014/06570A patent/ZA201406570B/en unknown
-
2015
- 2015-06-25 HK HK15106042.8A patent/HK1205528A1/xx unknown
-
2016
- 2016-09-14 US US15/264,900 patent/US10004739B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA029140B1 (ru) | 2018-02-28 |
BR112014021897B1 (pt) | 2022-06-14 |
MX2014010823A (es) | 2015-03-19 |
ZA201406570B (en) | 2015-12-23 |
ES2702305T3 (es) | 2019-02-28 |
WO2013133351A1 (ja) | 2013-09-12 |
AU2013228389A1 (en) | 2014-09-25 |
MX365214B (es) | 2019-05-27 |
US20150031703A1 (en) | 2015-01-29 |
PL2824181T3 (pl) | 2019-02-28 |
HK1205528A1 (en) | 2015-12-18 |
CN104379740A (zh) | 2015-02-25 |
US9481911B2 (en) | 2016-11-01 |
US10004739B2 (en) | 2018-06-26 |
KR102106962B1 (ko) | 2020-05-07 |
PH12014501918A1 (en) | 2014-11-24 |
CN104379740B (zh) | 2019-05-14 |
EP2824181B1 (en) | 2018-11-14 |
CA2865388A1 (en) | 2013-09-12 |
KR20140140070A (ko) | 2014-12-08 |
BR112014021897A2 (pt) | 2017-07-11 |
EP2824181A1 (en) | 2015-01-14 |
CA2865388C (en) | 2022-01-04 |
JPWO2013133351A1 (ja) | 2015-07-30 |
KR20230111270A (ko) | 2023-07-25 |
KR20200046135A (ko) | 2020-05-06 |
EP2824181A4 (en) | 2015-07-15 |
KR20220017512A (ko) | 2022-02-11 |
US20160375023A1 (en) | 2016-12-29 |
JP6107812B2 (ja) | 2017-04-05 |
PT2824181T (pt) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201491655A1 (ru) | Новый слитый fgfr3 | |
EA201591785A1 (ru) | Трициклические гетероциклы как ингибиторы белков бэт | |
EA201790876A1 (ru) | Способ контроля, предотвращения или лечения кровотечения | |
WO2014160499A3 (en) | Methods and compositions for detecting pancreatic cancer | |
EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
EA201690734A1 (ru) | Ингибиторы бромодомена | |
NZ730763A (en) | Methods of treating a tauopathy | |
EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
WO2014150751A3 (en) | Biomarkers associated with brm inhibition | |
EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
EP4276200A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
TW201613935A (en) | Tricyclic heterocycles as BET protein inhibitors | |
EA201590162A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
EA201690269A1 (ru) | Способы контроля уровней фукозилирования в белках | |
MX2015016472A (es) | Anticuerpo anti-vegf y composicion farmaceutica que comprende los mismos para prevenir, diagnosticar o tratar enfermedades relacionadas con cáncer o angiogénesis. | |
PH12018501070A1 (en) | Anti-pcsk9 antibody and use thereof | |
WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
EA201690559A1 (ru) | Способы определения ответа на терапию | |
FI20115328A (fi) | Uusia kutinaaseja, niiden tuottaminen ja käytöt | |
BR112015020054A2 (pt) | Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa | |
CL2012000938A1 (es) | Aptamero que se une al virus de la septicemia viral hemorrágica (vhsn); adn que codifica el aptamero, vector de expresión; transformante que se obtiene al introducir dicho vector; método para extraer el vhsv; composicion farmaceutica para tratar o prevenir la vhs; estuche de detección del vhsv. | |
EA201501137A1 (ru) | Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac | |
MX2017000831A (es) | Cuantificacion de tnfr2 : fc plegada erroneamente. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |